Tagged with access,

Singapore Claus Zieler discusses the Asia Pacific region’s importance to Bayer’s global operations, the company’s commitment to increasing its portfolio of innovative medicines, and the potential for innovation coming from Asian markets. Having spent four years in Japan previously, how have you had to adapt to serving the entire Asia Pacific…

USA In 2016, rumours of a weakening FDA followed a disappointing 16 new drugs approved for the full year. However, since the beginning of 2017 the FDA has approved 26 drugs; double the amount of the mid-year average since 2007. “The eight oncology treatments approved by the FDA this year represent…

Ukraine Natalia Zago, managing director of Takeda Ukraine, one of the leading international companies operating in the country, provides insights into her main priorities to drive the growth of the company under the conditions of significant changes in the pharmaceutical market and Ukrainian healthcare system.   Nobody can deny that Ukraine…

Indonesia Benoit Martineau, President Director at Sanofi Indonesia, explains the transformation of the Indonesian affiliate and reaffirms the strong commitment of Sanofi in helping the Indonesian government to successfully implement their patient access roadmap. Mr. Martineau, could you please introduce yourself to our international audience as well as your main areas…

Austria Dr. Wolfgang Andiel, president of the Austrian Association of Generic Medicines (OeGV, Österreichischer Generikaverband), which acts as a unified voice to represent generics companies in Austria, provides an in-depth analysis of the vicious cycle associated with establishing generics market share in Austria as well as the inconsistences of government regulations…

Colombia Aurobindo’s regional head, Kamlesh Thakkar, discusses how the company is truly benefiting the healthcare landscape in Colombia, while describing his experience in changing the mindset concerning the use of generics in the top hospitals of the country and shares the origins of Aurobindo’s healthier life campaign. To begin, Mr. Thakkar,…

Ukraine Dr. Natalya Gudz, head of the State Service of Ukraine on Medicines and Drugs Control (SMDC), provides her vision for the development of Ukraine’s key regulatory authority and the win-win relationship she wants to bolster between the pharmaceutical and healthcare companies operating in Ukraine and SMDC’s international counterparts. You took…

Indonesia Lin Neumann, Managing Director of AmCham Indonesia, highlights the opportunities in the Indonesian market, recent industry results, and the complex regulatory system in Indonesia: the main barrier to market access. You have been at AmCham since October 2014 after more than 20 years as a journalist around South-East Asia. What…

Indonesia Dr. Hasbullah Thabrany, chairman at the Center for Social Security Studies Universitas Indonesia (CSSUI) and Senior Health Care Financing Consultant to the National Social Security Council of Indonesia, explains the evolution of the national healthcare insurance system since its creation in 1968 as well as the path of development to…

Taiwan Derek Wang, Chairman of the board of the China Chemical & Pharmaceutical Group (CCPG), one of the leading pharmaceutical groups in Taiwan, provides insights into his strategies to consolidate CCPG’s leadership in Taiwan and China and accelerate the group’s market penetration in strategic countries such as Japan and the US,…

Taiwan Derek Wang, Chairman of the board of the China Chemical & Pharmaceutical Group (CCPG), one of the leading pharmaceutical groups in Taiwan, provides insights into his strategies to consolidate CCPG’s leadership in Taiwan and China and accelerate the group’s market penetration in strategic countries such as Japan and the US,…

Indonesia Parulian Simanjuntak, Executive Director at IPMG, explains the crucial role that MNCs should play within Indonesian universal healthcare coverage (JKN) and discusses the future challenges that should be addressed to enhance the national healthcare system. Indonesia is one of the strongest pharmaceutical markets within the region. Valued at USD 5.5…